UPDATE: Citadel Initiates Coverage on Forest Laboratories

Citadel Securities has published a report on Forest Laboratories FRX initiating coverage on the medicine developer. In the report, Citadel wrote, "We believe Forest revenue growth from fiscal 2013 to fiscal 2016 will be dependent on successful launches of recently approved drugs Teflaro, Daliresp, and Viibryd. The success of these drugs, combined with modest gains in Savella and Bystolic sales, could potentially offset revenue declines of Lexapro and Namenda." Citadel rated Forest Laboratories a Neutral with a price target of $36.00. Forest Laboratories closed Friday at $33.72.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst Ratingscitadel securitiesforest laboratoriesHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!